source
- Tyra Biosciences’ bladder cancer pill misses expected response rate in Phase 2 trialShares of Tyra Biosciences dropped about 20% after data from its Phase 2 study of a bladder cancer pill fell short of market expectations. The experimental drug, dabogratinib, is taken daily and t…
- Encoded Therapeutics raises $275 million in Series F round for Dravet syndrome programEncoded Therapeutics announced closing a Series F financing round that brought in $275 million. The round was led by GV with participation from an undisclosed healthcare investor. The new capital…